Prosensa accelerated or conditional approvals likely, says Roth Capital Roth Capital said its is "increasingly optimistic" that regulators won't focus on the outcome of Prosensa's disappointing phase 3 study for drisapersen and are likely to consider the totality of the data given the rare disease setting. The firm believes accelerated or conditional approvals for the drug are likely and it reiterates its Buy and $17 price target on the stock.
Prosensa upgraded to Overweight from Underweight at JPMorgan JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.